fbpx

Pulmonx Gains Regulatory Approval for Expanded Labeling for Emphysema Treatment

  • Posted by Jenna Widdison
  • On August 1, 2018
Pulmonx Gains Regulatory Approval for Expanded Labeling for Emphysema Treatment New labeling clears the way for the treatment of many more patients. January 10, 2012, Neuchâtel, Switzerland – Pulmonx SARL today announced that its European notified body has granted CE approval for expanded labeling of its Zephyr® endobronchial valve (EBV). The approval was based upon an...
Read More

Pulmonx Reports New Publication Confirms Efficacy of Emphysema Treatment

  • Posted by Jenna Widdison
  • On August 1, 2018
Zephyr® Endobronchial Valve (EBV) therapy guided by Chartis®Assessment is effective in a broad range of patients. May 10, 2012 ,Peseux, Switzerland, Pulmonx, an emerging leader in interventional pulmonology, announced today that the European Respiratory Journal has published the results of the...
Read More

Pulmonx Gets FDA Nod for U.S. Trial of Emphysema Therapy

  • Posted by Jenna Widdison
  • On August 1, 2018
IDE for Study of Zephyr® Endobronchial Valve Approved August 27, 2012, Redwood City, CA, USA - Pulmonx, an emerging leader in interventional pulmonology, announced today that the U.S. Food and Drug Administration (FDA) has approved its request for an Investigational Device Exemption (IDE) to...
Read More

Pulmonx Gets FDA Nod for U.S. Trial of Emphysema Therapy

  • Posted by Chris Kellett
  • On August 27, 2012
August 27, 2012, Redwood City, CA, USA - Pulmonx, an emerging leader in interventional pulmonology, announced today that the U.S. Food and Drug Administration (FDA) has approved its request for an Investigational Device Exemption (IDE) to commence a multi-center pivotal clinical trial.
Read More

Pulmonx Gains Regulatory Approval for Expanded Labeling for Emphysema Treatment

  • Posted by Chris Kellett
  • On January 10, 2012
January 10, 2012, Neuchâtel, Switzerland – Pulmonx SARL today announced that its European notified body has granted CE approval for expanded labeling of its Zephyr® endobronchial valve (EBV). The approval was based upon an independent review of clinical data from numerous studies including the recently completed Chartis multi-center study1 and the European VENT study (a randomized multi-center European trial of Zephyr EBV therapy)2.
Read More